ScholarIQanswers from OpenAlex & ORCID
Leslie A. Fecher
ResearcherPublications, citations & collaboration network
Leslie A. Fecher is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Leslie A. Fecher have?
ScholarIQindexed works
Leslie A. Fecher has 134 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Leslie A. Fecher have?
ScholarIQcitation count
Leslie A. Fecher has 15,642 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Leslie A. Fecher?
ScholarIQh-index
Leslie A. Fecher has an h-index of 38 in OpenAlex.
What is the i10-index of Leslie A. Fecher?
ScholarIQi10-index
Leslie A. Fecher has an i10-index of 59 in OpenAlex.
What is the ORCID of Leslie A. Fecher?
ScholarIQorcid
The ORCID for Leslie A. Fecher is on the source record.
What is the OpenAlex record for Leslie A. Fecher?
ScholarIQopenalex
The OpenAlex for Leslie A. Fecher is on the source record.
What are the most-cited papers on Leslie A. Fecher?
ScholarIQmost cited works
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda, Mark Sausen, Rebecca Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung T. Le, Robert Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung‐Mo Hong, Yuchen Jiao, Hartmut Juhl, Jaeyeon Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore‐Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba‐Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian‐Li Wang, Jon Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Díaz
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom, Siwen Hu‐Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach‐Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari Kendra, Richard C. Wu, Craig Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie A. Fecher, Pankaj Vats, Arul M. Chinnaiyan, Christopher D. Lao, Theodore S. Lawrence, Max S. Wicha, Junzo Hamanishi, Masaki Mandai, Ilona Kryczek, Weiping Zou
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith